To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: FDA Committee Recommends Celebrex For Arthritis URL: http://www.pslgroup.com/dg/C93CE.htm Doctor's Guide December 3, 1998
ST. LOUIS, MO -- Dec. 3, 1998 -- The United States Food and Drug Administration's arthritis advisory committee has recommended the approval of Searle and Pfizer's Celebrex(TM) (celecoxib) to treat patients with osteoarthritis and rheumatoid arthritis. However, the same committee said it could not immediately decide on whether to recommend the drug Celebrex for use in acute pain management. Celebrex is a member of a proposed new class of agents known as specific COX-2 inhibitors, which are designed to block the COX-2 enzyme activated in inflammation while sparing the activity of the COX-1 enzyme that protects the lining of the GI tract. The COX-1 enzyme also plays a role in blood clotting and kidney functions. Common side effects of NSAIDs, which are non-specific inhibitors of COX-1 and COX-2, include GI ulceration and bleeding, inhibition of platelet aggregation and interactions with other drugs. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.